CPX-351 is the Celator’s proprietary ‘liposomal combination of cytarabine and daunorubicin’ injection, indicated to treat acute myeloid leukemia (AML). The designation follows a positive opinion from the Committee
The alliance intends to develop new drugs for neglected tropical diseases (NTDs). The partnership is expected to generate in excess of $15m investment in drug development for NTDs
Octylseal is a wound closure tissue adhesive that is said to provide a strong, non-invasive alternative to topical sutures. It is also used as a microbial barrier or
This expansion is one of the series of projects that Albemarle is undertaking to meet the growing demand for its metallocene/single site finished catalyst business. A separate production
The company adds R&D and commercial scale fluid bed technology, OptiMelt hot melt extrusion, at its German facility and elevates cGMP compliance for handling of OEB class 3
Previstage GCC colorectal cancer staging test provides prognostic information based on the tumour burden measured at the molecular level in the lymph nodes, a key prognostic factor to
The OnkoMatch test is designed for solid tumor cancers such as lung, breast, colon, pancreas, thyroid and skin. The test will analyze 14 oncogenes, genes that drive cancer,
A Study to Characterise the Efficacy of Natalizumab on Disability (ASCEND) trial is a double-blind placebo-controlled study in which SPMS patients are randomised to receive either Tysabri 300
The acquisition will include blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). According to the agreement, Micromet’s Munich
The wholly owned subsidiary will provide pharmaceutical sales teams with operational and human resources (HR) support. The new business unit will expand Mission’s Northeastern US presence which also
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.